OLFactory Odour Stimulation and FOOD Preferences

NCT ID: NCT05869110

Last Updated: 2024-12-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-20

Study Completion Date

2024-08-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the present "OLFO-FOOD" clinical trial is to investigate, if olfactory stimulation impacts food choice, reference and calorie intake in humans with obesity assessed using a test buffet.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Overweight study participants will be included in this study. For the participants the study consists of the screening visit and main visit 1 and 2. In between the main visits there is a wash-out period of 1 week (7 days ± 3 days). In total, participants will have 3 visits. After the screening visit and before the main visit 1, odours will be assigned in a randomized order. Each participant will receive both odours. The two visits (main visit 1 and 2) will have the exact same procedures except for the olfactory odour.

Hunger, appetite, thirst, food perception, nausea, headache and mood will be assessed and the first blood samples will be collected. The participants will receive the aspUraclip® filled with 50 μl of either olfactory stimulation or placebo (propylene glycol), due to the computer-generated randomization order. The "aspUraclip®" will be clipped to the nasal septum for 15 minutes. After olfactory stimulation, vital parameters will be measured and blood samples will be taken. Participants will rate hunger, appetite, thirst, nausea, headache, mood, as well as local nose irritation, odour intensity and odour perception. Directly afterwards, the participants choose food ad libitum from a test-buffet. Participants will have 2 hours to eat from the buffet, but can finish earlier if they wish. Eating time will be recorded. After finishing their meal, vitals will be measured, blood samples will be collected and the participants will rate hunger, appetite (general, carbohydrates, meat, dairy foods, vegetables, fruits, sweets, salty foods), thirst, nausea, headache, mood, food taste, food taste intensity, food scent intensity and food scent perception on a 10-point VAS (visual analogue scale). 2 hours after the start of the test-buffet, patients will rate the same questions on a VAS again, vitals and blood samples will be taken. If the participants eat throughout the 2-hour-timespan of the test-buffet and don't stop early, there will be only one measurement (vitals, VAS, BS) after 2 hours, when the test-buffet ends. Food intake will be measured by weighing the food before and after consumption. Following the test-buffet, patients will have a resting phase of 2 hours. During this phase, patients are free to read, listen to music or similar. After the 2 hour resting phase, vitals will be measured, blood samples collected and VAS-questions asked.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

olfactory stimulation Hunger Appetite calorie intake food choice metabolic parameters

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomized, placebo-controlled, single-blind, cross-over, single-centre trial
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants
Study participants will not be informed which substances are investigated

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental Intervention

Olfactory stimulation

Group Type EXPERIMENTAL

Effects of odours on calorie intake, food choice and metabolic parameters

Intervention Type OTHER

Evaluation of the effects of olfactory stimulation compared to placebo on calorie intake and preference of food during a test-buffet.

Odours will be assigned in a randomized order. Each participant will receive both odours, in between there will be a wash-out period of 1 week.

Placebo

Propylene glycol

Group Type PLACEBO_COMPARATOR

Effects of odours on calorie intake, food choice and metabolic parameters

Intervention Type OTHER

Evaluation of the effects of olfactory stimulation compared to placebo on calorie intake and preference of food during a test-buffet.

Odours will be assigned in a randomized order. Each participant will receive both odours, in between there will be a wash-out period of 1 week.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Effects of odours on calorie intake, food choice and metabolic parameters

Evaluation of the effects of olfactory stimulation compared to placebo on calorie intake and preference of food during a test-buffet.

Odours will be assigned in a randomized order. Each participant will receive both odours, in between there will be a wash-out period of 1 week.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-60 years
* Written informed consent
* BMI ≥30 kg/m2
* Normosmia (as defined by Sniffin' Sticks Test)

Exclusion Criteria

* Known allergy to olfactory stimulation substance, citrus fruits, citrus flavours, citrus food products
* Lactose-intolerance, celiac disease or non-celiac wheat sensitivity
* Diet other than omnivore or vegetarian
* Eating disorder (now or in the past)
* Dysphagia
* Acute disease affecting food intake
* Acute upper respiratory tract infection, acute or chronic sinusitis
* Severe visual impairment (vision \<10%)
* Surgical intervention of the nasal cavity or the paranasal sinus
* Current illicit drug abuse including daily marijuana and CBD (Cannabidiol) consumption (alcohol ≤2 drinks per day allowed)
* Any kind of severe chronic disease (e.g. severe heart failure, active cancer disease)
* Type 1 and 2 diabetes mellitus
* Treatment with insulin-sensitizing drugs within the last 3 months
* Treatment with Glucagon-like Peptide 1 (GLP1)-analoga
* History of neurodegenerative diseases, severe head trauma
* Severe renal impairment (e.g. estimated glomerular filtration rate \<30 ml/min/m2)
* Known liver cirrhosis or other severe liver impairment
* Use of any kind of decongestant more than twice a week
* Uncontrolled dysthyroidism
* Uncontrolled hypertension
* Regular use of psychopharmaceutic drugs
* Study participants aims to start a new diet or exercise program during the study
* Bariatric surgery
* Pregnancy/Lactation
* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
* Participation in an interventional study within the last 3 months
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Basel, Switzerland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Katharina Timper, Prof. Dr. med.

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Basel, Switzerland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Basel

Basel, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-00511, kt23Timper

Identifier Type: -

Identifier Source: org_study_id